To receive the Femtech World newsletter, sign up here.
News
Medical device company expands pelvic health portfolio with new acquisition
More and more people are looking to treat pelvic and sexual health conditions at home
The Oxford-based medical device company Owen Mumford has acquired the Danish pelvic floor brand Empelvic.
Owen Mumford is a medical device manufacturer with a global presence across the UK, Europe, US and Asia. The acquisition is hoped to bolster the company’s pelvic and sexual health portfolio with accessible solutions aimed at helping consumers treat various health concerns.
Research suggests that female sexual dysfunction, stress incontinence and pain are common, but largely unaddressed.
A study, published in the American Journal of Obstetrics & Gynecology, found that nearly 70 percent of women who discussed their plans to conceive with their doctor did not talk about their sex life in these conversations, and more than half of this group said that their provider did not bring up this subject in these conversations.
More and more people are instead looking to treat pelvic and sexual health conditions at home.
Empelvic, a Copenhagen-based start-up, aims to provide an easy way to help people struggling with conditions, such as stress incontinence and vaginismus, by training their pelvic floor muscles.
The device the company has developed is non-invasive and is designed to connect with the pelvic floor. When sat on, the cushion helps to increase awareness of the pelvic floor, Empelvic claims, making it easier to connect with the individual muscles.
Adam Mumford, director of medical devices at Owen Mumford, said: “The acquisition of Empelvic reinforces our commitment to comprehensive health solutions for intimate conditions.
“By combining Owen Mumford’s global expertise with Empelvic’s innovative product, we aim to provide enhanced support and choices for individuals seeking pelvic health solutions.”
Midwife Gry Senderovitz, Empelvic co-founder, said: “As a company with roots in Denmark, this strategic move allows us to leverage Owen Mumford’s extensive reach and resources, ultimately enhancing our ability to serve individuals seeking pelvic health solutions in Scandinavia and beyond.
“We look forward to the positive impact this acquisition will have on the lives of many as we continue our mission to make a meaningful difference in pelvic health and wellbeing.”
Empelvic will join Owen Mumford’s existing pelvic and sexual health portfolio alongside its Amielle Comfort and Care vaginal dilators and the Rapport vacuum therapy device.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Hormonal health3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Diagnosis2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







